ENDRA Life Sciences Stock Surges 177% Amid ISO Certification

ENDRA Life Sciences Inc. (NASDAQ: NDRA) Overview

ENDRA Life Sciences Inc., headquartered in Ann Arbor, Michigan, develops ultrasound technologies under its Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform. Founded on July 18, 2007, the company aims to provide clinicians with point-of-care tools for quantifying tissue composition, function, and temperature, capabilities traditionally reliant on biopsy and MRI.

Corporate Structure and Operations

ENDRA operates with a workforce of 11–50 employees focused on research, development, and regulatory compliance. The company maintains a Quality Management System certified under ISO 13485:2016 & EN ISO 13485:2016 (Certificate MD 697226, effective April 2, 2025–April 1, 2028). Its primary R&D efforts center on TAEUS applications for liver fat quantification and monitoring tissue temperature during certain surgical procedures.

Ultrasound Technology by National Cancer Institute

Recent Developments

• Stock Performance (July 8, 2025): NDRA shares closed at USD 9.60, reflecting a 177.73% increase on volume of 16,489,280 shares traded on the NASDAQ exchange.
• ISO Certification: On April 2, 2025, ENDRA’s quality management system achieved ISO 13485:2016 certification, valid through April 1, 2028.
• SEC Filings:
  • 10-Q (May 15, 2025): Quarterly report indicating ongoing R&D investment and cash runway commentary.
  • 8-K (May 30, 2025; June 11, 2025): Current reports that disclosed corporate updates, including unregistered share issuances and regulatory disclosures.
• Investor Relations: The company is advancing its next-generation TAEUS system, which targets the steatotic liver disease market (NAFLD/NASH), impacting over two billion people worldwide.

Financial and Strategic Analysis

In the first quarter of fiscal 2025, ENDRA reported a loss per share of USD 1.86, compared to an estimated loss of USD 3.91, resulting in a net loss of USD 1.04 million, down from USD 4.15 million in the prior quarter. This reflects ongoing R&D and expense management efforts. Analysts’ price forecasts for NDRA show a consensus target of USD 46.00, reflecting anticipated developments related to clinical trials and potential partnerships.

Strategically, ENDRA positions TAEUS as a cost-effective, portable alternative to MRI for fat quantification in the liver. The platform's ability to deliver real-time biomarkers at the point of care supports its applicability in hepatology and metabolic disease management.

Market Position and Industry Context

Non-Alcoholic Fatty Liver Disease (NAFLD) and its progression to Non-Alcoholic Steatohepatitis (NASH) are associated with significant clinical and economic challenges, projected to cost the U.S. healthcare system over USD 100 billion annually. ENDRA’s TAEUS addresses a critical gap by facilitating tissue analysis in outpatient settings. Competing modalities include magnetic resonance elastography and ultrasound-based shear wave systems, but currently available technologies do not combine composition, function, and temperature metrics in a single device.

TL;DR

On July 8, 2025, ENDRA’s stock increased by 177.73% to USD 9.60 on NASDAQ with notable trading volume. The company attained ISO 13485:2016 certification until 2028 and reported a Q1 2025 EPS loss of USD 1.86 against an expected loss of USD 3.91. With a market targeting over two billion individuals impacted by NAFLD/NASH and analyst price targets set at USD 46.00, ENDRA’s outlook will depend on the clinical validation of its TAEUS platform and potential partnerships.